PMID- 26886894
OWN - NLM
STAT- MEDLINE
DCOM- 20160614
LR  - 20160218
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
VI  - 57
IP  - 2
DP  - 2016 Feb
TI  - Topical Application of Interleukin-28A Attenuates Allergic Conjunctivitis in an 
      Ovalbumin-Induced Mouse Model.
PG  - 604-10
LID - 10.1167/iovs.15-18457 [doi]
AB  - PURPOSE: Allergic conjunctivitis (AC) is an immunoglobulin E (IgE)-mediated and 
      helper T cell 2 (Th2)--cell-mediated disease characterized by conjunctival 
      eosinophilic infiltration. Previous study shows that IL-28A had anti-allergic 
      activity in airway disease. In this study, we examined the effect of IL-28A on a 
      mouse model of ovalbumin (OVA)-induced experimental allergic conjunctivitis 
      (EAC). METHODS: Mouse EAC was induced by topical application of OVA after 
      intraperitoneal (IP) sensitization with OVA in aluminum hydroxide (ALUM). 
      Interleukin-28A was administered 1 hour before OVA challenge. Allergic 
      conjunctivitis symptoms, eosinophil infiltration in the conjunctiva, 
      antigen-specific IgE in the serum, and Th2 cytokine production by lymph node 
      cells and splenocytes were subsequently analyzed. RESULTS: Topical application of 
      IL-28A to OVA-induced EAC reduced clinical symptoms, serum OVA-specific IgE, and 
      the infiltration of eosinophils in the conjunctiva. In addition, topical 
      administration of IL-28A suppressed the expression of IL-4, IL-5, and IL-13 
      (Th2-type cytokine) but promoted the expression of IFN-gamma (Th1-type cytokine) by 
      splenocytes and cervical lymph node cells in EAC mice. Immunofluorescence 
      staining showed decrease expression of IL-4 and IL-5 in IL-28A-treated EAC 
      conjunctiva. CONCLUSIONS: Interleukin-28A shows therapeutic potential for 
      allergic conjunctival inflammation.
FAU - Chen, Jianping
AU  - Chen J
FAU - Zhang, Jing
AU  - Zhang J
FAU - Zhao, Ruijuan
AU  - Zhao R
FAU - Jin, Jiayi
AU  - Jin J
FAU - Yu, Ying
AU  - Yu Y
FAU - Li, Weihua
AU  - Li W
FAU - Wang, Wencong
AU  - Wang W
FAU - Zhou, Hongyan
AU  - Zhou H
FAU - Su, Shao Bo
AU  - Su SB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (IL28A protein, mouse)
RN  - 0 (Interleukins)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Antibodies, Anti-Idiotypic/blood/immunology
MH  - Cells, Cultured
MH  - Conjunctiva/drug effects/immunology/pathology
MH  - Conjunctivitis, Allergic/chemically induced/*drug therapy/immunology
MH  - Disease Models, Animal
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Eosinophils/pathology
MH  - Female
MH  - Immunoglobulin E/immunology
MH  - Immunohistochemistry
MH  - Interleukins/*administration & dosage
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Ovalbumin/toxicity
MH  - T-Lymphocytes/immunology/pathology
EDAT- 2016/02/18 06:00
MHDA- 2016/06/15 06:00
CRDT- 2016/02/18 06:00
PHST- 2016/02/18 06:00 [entrez]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2016/06/15 06:00 [medline]
AID - 2493124 [pii]
AID - 10.1167/iovs.15-18457 [doi]
PST - ppublish
SO  - Invest Ophthalmol Vis Sci. 2016 Feb;57(2):604-10. doi: 10.1167/iovs.15-18457.